Immunogen Inc.

NAS: IMGN

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Immunogen Inc.

After Hours

IMGN

/zigman2/quotes/208003500/composite

4.50

Change

+0.11 +2.51%

Volume

Volume 31,294

Jun 27, 2022, 7:57 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/208003500/composite

Previous close

$ 4.31

$ 4.39

Change

+0.08 +1.86%

Day low

Day high

$4.23

$4.45

Open: 4.36

52 week low

52 week high

$3.10

$7.77

Market cap

$950.51M

Average volume

3.82M

P/E ratio

N/A

Rev. per Employee

$659,019

EPS

-0.60

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/imgn

MarketWatch News on IMGN

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

7:59 a.m. May 23, 2022

- Jaimy Lee
ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion

7:40 a.m. Feb. 15, 2022

- Ciara Linnane
ImmunoGen shares jump 7% premarket

7:35 a.m. Feb. 15, 2022

- Ciara Linnane
ImmunoGen unveils license agreement of Novel Camptothecin ADC Platform with Eli Lilly for up to $1.7 bln

7:34 a.m. Feb. 15, 2022

- Ciara Linnane
ImmunoGen will receive an initial upfront payment of $13 mln, and up to $35 mln more for meeting targets

7:35 a.m. Feb. 15, 2022

- Ciara Linnane
Immunogen started at outperform with $18 stock price target at BMO Capital

2:51 p.m. Feb. 11, 2022

- Tomi Kilgore
People are spending over three times more money ‘gambling’ on hot stocks than at casinos and on lottery tickets and sports betting

9:32 a.m. Oct. 31, 2020

- Mark Hulbert
Bed Bath & Beyond and 3 more stocks showing momentum

1:50 p.m. Dec. 19, 2019

- Harry Boxer
ImmunoGen shares rise on ovarian cancer study

5:00 p.m. Dec. 17, 2019

- Jaimy Lee
ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers

6:52 a.m. May 16, 2019

- Sarah Toy
ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug

8:22 a.m. May 15, 2019

- Sarah Toy
Immunogen's stock plunges 30% premarket after FDA recommends new phase 3 trial of cancer treatment

7:49 a.m. May 15, 2019

- Tomi Kilgore
Immunogen downgraded to underweight from neutral at J.P. Morgan

6:55 a.m. March 19, 2019

- Tomi Kilgore
The Dow Bounces Back Because No News Is Good News — for Now

12:57 p.m. March 5, 2019

- Barron's Online
Immunogen upgraded to equal weight at Morgan Stanley

10:55 a.m. March 5, 2019

- Tomi Kilgore
S&P 500 closes above 2,800 for the first time in nearly 4 months on trade optimism

5:27 p.m. March 1, 2019

- Sue Chang
Immunogen stock the most actively traded on major U.S. exchanges, with volume above 13.8 mln shares

10:50 a.m. March 1, 2019

- Tomi Kilgore
Immunogen's stock plummets 50% to pace all NYSE, Nasdaq decliners

10:49 a.m. March 1, 2019

- Tomi Kilgore
Immunogen's stock plunges on premarket-leading trading volume of 3.2 mln shares

9:20 a.m. March 1, 2019

- Tomi Kilgore
Immunogen's stock extends loss, plunges 50.2% premarket after failed trial

9:20 a.m. March 1, 2019

- Tomi Kilgore
Loading more headlines...